Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN
机构：[1]Department of Medicine, Georgia Cancer Center at Augusta University, Augusta, GA, USA.[2]Department of Hematology, Peking University People’s Hospital, Beijing, China.[3]Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.[4]Department of Hematology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.[5]Department of Hematology, West China Hospital of Sichuan University, Chengdu, China.四川大学华西医院[6]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.[7]Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany.[8]Hematology Department, Eulji Medical Center, Leukemia Omics Research Institute, Eulji University, Seoul, Republic of Korea.[9]Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.[10]Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA[11]Bristol Myers Squibb, Princeton, NJ, USA[12]Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Early molecular response (EMR) at 3 months is predictive of improved overall survival (OS) and progression-free survival (PFS) in patients with chronic myeloid leukemia in the chronic phase (CML-CP). Although about one-third of patients treated with first-line imatinib do not achieve EMR, long-term OS and PFS are still observed in most patients. DASCERN (NCT01593254) is a prospective, phase IIb, randomized trial evaluating a switch to dasatinib in patients who have not achieved EMR after 3 months of treatment with first-line imatinib. Early analysis demonstrated an improved major molecular response (MMR) rate at 12 months with dasatinib versus imatinib (29% vs. 13%, P=0.005). Here, we report results from the final 5-year follow-up. In total, 174 patients were randomized to dasatinib and 86 to remain on imatinib. Forty-six (53%) patients who remained on imatinib but subsequently experienced failure were allowed to cross over to dasatinib per protocol. At a minimum follow-up of 60 months, the cumulative MMR rate was significantly higher in patients randomized to dasatinib versus imatinib (77% vs. 44%, P.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|1 区医学
小类|2 区血液学
最新[2023]版：
大类|1 区医学
小类|2 区血液学
第一作者：
第一作者机构：[1]Department of Medicine, Georgia Cancer Center at Augusta University, Augusta, GA, USA.[*1]Georgia Cancer Center at Augusta University 1410 Laney Walker Blvd. CN2222, Augusta, GA 30912
通讯作者：
通讯机构：[1]Department of Medicine, Georgia Cancer Center at Augusta University, Augusta, GA, USA.[*1]Georgia Cancer Center at Augusta University 1410 Laney Walker Blvd. CN2222, Augusta, GA 30912
推荐引用方式(GB/T 7714)：
Cortes Jorge E,Jiang Qian,Wang Jianxiang,et al.Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN[J].Haematologica.2024,doi:10.3324/haematol.2023.283428.
APA：
Cortes Jorge E,Jiang Qian,Wang Jianxiang,Weng Jianyu,Zhu Huanling...&Saglio Giuseppe.(2024).Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN.Haematologica,,
MLA：
Cortes Jorge E,et al."Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN".Haematologica .(2024)
医学